The role of SPECT/CT in radioembolization of liver tumours

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue SUPPL. 1, 2014, Pages

  Ahmadzadehfar, Hojjat ^a   Duan, Heying ^b   Haug, Alexander R ^b   Walrand, Stephan ^c   Hoffmann, Martha ^b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

90Y microspheres; Liver tumours; Radioembolization; SPECT CT

Indexed keywords

RADIOPHARMACEUTICAL AGENT; YTTRIUM 90; YTTRIUM;

ARTIFICIAL EMBOLISM; BREMS RADIATION; CANCER RADIOTHERAPY; COIL EMBOLIZATION; DOSIMETRY; GASTRODUODENAL ARTERY; HUMAN; LIVER CIRCULATION; LIVER PERFUSION; LIVER TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIATION EXPOSURE; RADIOEMBOLIZATION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT PLANNING; VASCULARIZATION; CARCINOMA, HEPATOCELLULAR; COMPUTER ASSISTED TOMOGRAPHY; LIVER NEOPLASMS; MULTIMODAL IMAGING; PROCEDURES; RADIATION DOSE;

CARCINOMA, HEPATOCELLULAR; EMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS; MULTIMODAL IMAGING; RADIATION DOSAGE; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; YTTRIUM RADIOISOTOPES;

EID: 84905591431     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2675-5     Document Type: Review

References (80)

1. Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011;54:868-78. doi:10. 1002/hep. 24451.
2. Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140:497-507. e2. doi:10. 1053/j.gastro.2010.10.049.
3. Welsh JS, Kennedy AS, Thomadsen B. Selective Internal Radiation Therapy (SIRT) for liver metastases secondary to colorectal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2006;66:S62-73. doi:10. 1016/j.ijrobp. 2005.09.011.
4. Campbell AM, Bailey IH, Burton MA. Analysis of the distribution of intra-arterial microspheres in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol. 2000;45:1023-33.
5. Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol. 2006;17:1251-78.
6. Lien WM, Ackerman NB. The blood supply of experimental liver metastases. II. A microcirculatory study of the normal and tumor vessels of the liver with the use of perfused silicone rubber. Surgery. 1970;68:334-40.
7. Vente MA, Nijsen JF, De Wit TC, Seppenwoolde JH, Krijger GC, Seevinck PR, et al. Clinical effects of transcatheter hepatic arterial embolization with holmium-166 poly (L-lactic acid) microspheres in healthy pigs. Eur J Nucl Med Mol Imaging. 2008;35:1259-71. doi: 10.1007/s00259-008-0747-8.
8. Lin YC, Tsai SC, Hung GU, Lee JC, Huang YS, Lin WY. Direct injection of (188) Re-microspheres in the treatment of hepatocellular carcinoma: compared with traditional percutaneous ethanol injection: an animal study. Nuklearmedizin. 2005;44:76-80. doi:10.1267/NUKL05030076.
9. Liu L, Jiang Z, Teng GJ, Song JZ, Zhang DS, Guo QM, et al. Clinical and experimental study on regional administration of phosphorus 32 glass microspheres in treating hepatic carcinoma. World J Gastroenterol. 1999;5:492-505.
10. Amoui M, Pirayesh E, Akhlaghpoor S, Tolooee B, Poorbeigi H, Sheibani S. Correlation between CT/MRI and bremsstrahlung SPECT of 32P after radioembolization of hepatic tumors. Iran J Radiol. 2010;7:1-5.
11. Ahmadzadehfar H, Biersack HJ, Ezziddin S. Radioembolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med. 2010;40:105-21. doi:10.1053/j.semnuclmed.2009.11.001.
12. Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007;68:13-23. doi:10.1016/j. ijrobp. 2006.11.060.
13. Murthy R, Nunez R, Szklaruk J, Erwin W, Madoff DC, Gupta S, et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics. 2005;25 Suppl 1:S41-55. doi:10. 1148/rg.25si055515.
14. Riaz A, Lewandowski RJ, Kulik LM, Mulcahy MF, Sato KT, Ryu RK, et al. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol. 2009;20:1121-30. doi:10.1016/j.jvir.2009.05.030. quiz 31.
15. Yip D, Allen R, Ashton C, Jain S. Radiation-induced ulceration of the stomach secondary to hepatic embolization with radioactive yttrium microspheres in the treatment of metastatic colon cancer. J Gastroenterol Hepatol. 2004;19:347-9.
16. Carretero C, Munoz-Navas M, Betes M, Angos R, Subtil JC, Fernandez-Urien I, et al. Gastroduodenal injury after radioembolization of hepatic tumors. Am J Gastroenterol. 2007;102:1216-20. doi:10.1111/j.1572-0241.2007.01172.x.
17. Leung TW, Lau WY, Ho SK, Ward SC, Chow JH, Chan MS, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys. 1995;33:919-24.
18. Murthy R, Brown DB, Salem R, Meranze SG, Coldwell DM, Krishnan S, et al. Gastrointestinal complications associated with hepatic arterial yttrium-90 microsphere therapy. J Vasc Interv Radiol. 2007;18:553-62. doi:10.1016/j.jvir. 2007.02.002.
19. Salem R, Parikh P, Atassi B, Lewandowski RJ, Ryu RK, Sato KT, et al. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol. 2008;31:431-8. doi:10.1097/COC. 0b013e318168ef65.
20. Atassi B, Bangash AK, Lewandowski RJ, Ibrahim S, Kulik L, Mulcahy MF, et al. Biliary sequelae following radioembolization with yttrium-90 microspheres. J Vasc Interv Radiol. 2008;19:691-7. doi:10.1016/j.jvir.2008.01.003.
21. Covey AM, Brody LA, Maluccio MA, Getrajdman GI, Brown KT. Variant hepatic arterial anatomy revisited: digital subtraction angiography performed in 600 patients. Radiology. 2002;224:542-7.
22. Ahmadzadehfar H, Sabet A, Biermann K, Muckle M, Brockmann H, Kuhl C, et al. The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment. J Nucl Med. 2010;51:1206-12. doi: 10.2967/jnumed.109.074559.
23. Lenoir L, Edeline J, Rolland Y, Pracht M, Raoul JL, Ardisson V, et al. Usefulness and pitfalls of MAA SPECT/CT in identifying digestive extrahepatic uptake when planning liver radioembolization. Eur J Nucl Med Mol Imaging. 2012;39:872-80. doi:10.1007/s00259-011-2033-4.
24. Hamami ME, Poeppel TD, Muller S, Heusner T, Bockisch A, Hilgard P, et al. SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer. J Nucl Med. 2009;50:688-92. doi:10.2967/jnumed.108. 058347.
25. Denecke T, Ruhl R, Hildebrandt B, Stelter L, Grieser C, Stiepani H, et al. Planning transarterial radioembolization of colorectal liver metastases with yttrium 90 microspheres: evaluation of a sequential diagnostic approach using radiologic and nuclear medicine imaging techniques. Eur Radiol. 2008;18:892-902. doi:10.1007/s00330-007-0836-2.
26. 99m macroaggregated albumin: a single center's experience. Cardiovasc Intervent Radiol. 2012;35:1083-93. doi:10.1007/s00270-011-0252-5.
27. Giammarile F, Bodei L, Chiesa C, Flux G, Forrer F, Kraeber-Bodere F, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2011;38:1393-406. doi:10.1007/s00259-011-1812-2.
28. Ahmadzadehfar H, Muckle M, Sabet A, Wilhelm K, Kuhl C, Biermann K, et al. The significance of bremsstrahlung SPECT/CT after yttrium-90 radioembolization treatment in the prediction of extrahepatic side effects. Eur J Nucl Med Mol Imaging. 2012;39:309-15. doi:10.1007/s00259-011-1940-8.
29. Ahmadzadehfar H, Sabet A, Muckle M, Wilhelm K, Reichmann K, Biersack HJ, et al. 99mTc-MAA/90Y-Bremsstrahlung SPECT/CT after simultaneous Tc-MAA/90Y-microsphere injection for immediate treatment monitoring and further therapy planning for radioembolization. Eur J Nucl Med Mol Imaging. 2011;38:1281-8. doi:10.1007/s00259-011-1751-y.
30. Mansberg R, Sorensen N, Mansberg V, Van Der Wall H. Yttrium 90 Bremsstrahlung SPECT/CT scan demonstrating areas of tracer/tumour uptake. Eur J Nucl Med Mol Imaging. 2007;34:1887. doi: 10.1007/s00259-007-0536-9.
31. Fabbri C, Sarti G, Cremonesi M, Ferrari M, Di Dia A, Agostini M, et al. Quantitative analysis of 90Y Bremsstrahlung SPECT-CT images for application to 3D patient-specific dosimetry. Cancer Biother Radiopharm. 2009;24:145-54. doi:10.1089/cbr.2008.0543.
32. Strahlenschutzkommission Sd. Radionuklidtherapie mittels selektiver intraarterieller Radiotherapie (SIRT) und intravasale Bestrahlung mit offenen Radionukliden. In: Strahlenschutzkommission, editor. Bonn; 2009
33. Sabet A, Ahmadzadehfar H, Muckle M, Haslerud T, Wilhelm K, Biersack HJ, et al. Significance of oral administration of sodium perchlorate in planning liver-directed radioembolization. J Nucl Med. 2011;52:1063-7. doi:10.2967/jnumed.110.083626.
34. Uliel L, Royal HD, Darcy MD, Zuckerman DA, Sharma A, Saad NE. From the angio suite to the gamma-camera: vascular mapping and 99mTc-MAA hepatic perfusion imaging before liver radioembolization - a comprehensive pictorial review. J Nucl Med. 2012;53:1736-47. doi:10.2967/jnumed.112.105361.
35. Van De Wiele C, Stellamans K, Brugman E, Mees G, De Spiegeleer B, D'Asseler Y, et al. Quantitative pretreatment VOI analysis of liver metastases. (99m) Tc-MAA SPECT/CT and FDG PET/CT in relation with treatment response to SIRT. Nuklearmedizin. 2013;52:21-7.
36. 99m-MAA SPECT/CT: a case series, technical discussion and clinical implications. Ann Nucl Med. 2011;25:669-76. doi:10.1007/s12149-011-0516-9.
37. Naymagon S, Warner RR, Patel K, Harpaz N, Machac J, Weintraub JL, et al. Gastroduodenal ulceration associated with radioembolization for the treatment of hepatic tumors: an institutional experience and review of the literature. Dig Dis Sci. 2010;55:2450-8. doi:10.1007/s10620-010-1156-y.
38. Lauenstein TC, Heusner TA, Hamami M, Ertle J, Schlaak JF, Gerken G, et al. Radioembolization of hepatic tumors: flow redistribution after the occlusion of intrahepatic arteries. Rofo. 2011;183:1058-64. doi:10.1055/s-0031-1281767.
39. McWilliams JP, Kee ST, Loh CT, Lee EW, Liu DM. Prophylactic embolization ofthe cystic artery before radioembolization: feasibility, safety, and outcomes. Cardiovasc Intervent Radiol. 2011;34:786-92. doi:10.1007/s00270-010-0021-x.
40. Chernyak I, Bester L, Freund J, Richardson M. Anterior abdominal wall uptake in intrahepatic arterial brachytherapy with yttrium-90 sir spheres for hepatic malignancy. Clin Nucl Med. 2008;33:677-80. doi:10.1097/RLU. 0b013e318184b44f.
41. Kao YH, Tan AE, Khoo LS, Lo RH, Chow PK, Goh AS. Hepatic falciform ligament Tc-99 m-macroaggregated albumin activity on SPECT/CT prior to Yttrium-90 microsphere radioembolization: prophylactic measures to prevent non-target microsphere localization via patent hepatic falciform arteries. Ann Nucl Med. 2011;25:365-9. doi: 10.1007/s12149-010-0464-9.
42. Ahmadzadehfar H, Mohlenbruch M, Sabet A, Meyer C, Muckle M, Haslerud T, et al. Is prophylactic embolization of the hepatic falciform artery needed before radioembolization in patients with 99mTc-MAA accumulation in the anterior abdominal wall? Eur J Nucl Med Mol Imaging. 2011;38:1477-84. doi:10.1007/s00259-011-1807-z.
43. 99m) technetium-albumin macroaggregates. Cardiovasc Intervent Radiol. 2011;34:1074-9. doi:10.1007/s00270-010-0088-4.
44. Burgmans MC, Too CW, Kao YH, Goh AS, Chow PK, Tan BS, et al. Computed tomography hepatic arteriography has a hepatic falciform artery detection rate that is much higher than that of digital subtraction angiography and 99mTc-MAA SPECT/CT: implications for planning 90Y radioembolization? Eur J Radiol. 2012;81:3979-84. doi:10.1016/j.ejrad.2012.08.007.
45. Baba Y, Miyazono N, Ueno K, Kanetsuki I, Nishi H, Inoue H, et al. Hepatic falciform artery. Angiographic findings in 25 patients. Acta Radiol. 2000;41:329-33.
46. Leong QM, Lai HK, Lo RG, Teo TK, Goh A, Chow PK. Radiation dermatitis following radioembolization for hepatocellular carcinoma: a case for prophylactic embolization of a patent falciform artery. J Vasc Interv Radiol. 2009;20:833-36. doi:10.1016/j.jvir.2009.03.011.
47. Garin E, Lenoir L, Rolland Y, Edeline J, Mesbah H, Laffont S, et al. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med. 2012;53:255-63. doi:10.2967/jnumed. 111.094235.
48. Flamen P, Vanderlinden B, Delatte P, Ghanem G, Ameye L, Van Den Eynde M, et al. Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres. Phys Med Biol. 2008;53:6591-603. doi:10.1088/0031-9155/53/ 22/019.
49. Garin E, Lenoir L, Rolland Y, Laffont S, Pracht M, Mesbah H, et al. Effectiveness of quantitative MAA SPECT/CT for the definition of vascularized hepatic volume and dosimetric approach: phantom validation and clinical preliminary results in patients with complex hepatic vascularization treated with yttrium-90-labeled microspheres. Nucl Med Commun. 2011;32:1245-55. doi:10.1097/MNM. 0b013e32834a716b.
50. Garin E, Lenoir L, Edeline J, Laffont S, Mesbah H, Poree P, et al. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging. 2013;40:1057-68. doi:10.1007/s00259-013- 2395-x.
51. Salem R, Lewandowski RJ, Gates VL, Nutting CW, Murthy R, Rose SC, et al. Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol. 2011;22:265-78. doi:10. 1016/j.jvir.2010.10.029.
52. 99m macroaggregated albumin in the determination of tumour to non-tumour uptake ratio in hepatocellular carcinoma. Br J Radiol. 1994;67:136-9.
53. Fox RA, Klemp PF, Egan G, Mina LL, Burton MA, Gray BN. Dose distribution following selective internal radiation therapy. Int J Radiat Oncol Biol Phys. 1991;21:463-7.
54. Burton MA, Gray BN, Klemp PF, Kelleher DK, Hardy N. Selective internal radiation therapy: distribution of radiation in the liver. Eur J Cancer Clin Oncol. 1989;25:1487-91.
55. Ho S, Lau WY, Leung TW, Chan M, Ngar YK, Johnson PJ, et al. Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med. 1996;23:947-52.
56. Chiesa C, Maccauro M, Romito R, Spreafico C, Pellizzari S, Negri A, et al. Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90) Y microspheres: the experience of the National Tumor Institute of Milan. Q J Nucl Med Mol Imaging. 2011;55:168-97.
57. Chiesa C, Mira M, Maccauro M, Romito R, Spreafico C, Sposito C, et al. A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres. Q J Nucl Med Mol Imaging. 2012;56:503-8.
58. Jiang M, Fischman A, Nowakowski F, Heiba S, Zhang Z, Knesaurek K, et al. Segmental perfusion differences on paired Tc-99 m Macroaggregated Albumin (MAA) hepatic perfusion imaging and Yttrium-90 (Y-90) bremsstrahlung imaging studies in SIR-Sphere radioembolization: associations with Angiography. J Nucl Med Radiat Ther. 2012;3:122.
59. Wondergem M, Smits ML, Elschot M, De Jong HW, Verkooijen HM, Van Den Bosch MA, et al. 99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolization. J Nucl Med. 2013;54:1294-301. doi:10. 2967/jnumed.112.117614.
60. Basciano C, Kleinstreuer C, Kennedy A. Computational fluid dynamics modeling of 90Y microspheres in human hepatic tumors. J Nucl Med Radiat Ther. 2011;2:1-6.
61. Walrand S, Lhommel R, Goffette P, Van Den Eynde M, Pauwels S, Jamar F. Hemoglobin level significantly impacts the tumor cell survival fraction in humans after internal radiotherapy. EJNMMI Res. 2012;2:20. doi:10.1186/2191- 219X-2-20.
62. Gupta T, Virmani S, Neidt TM, Szolc-Kowalska B, Sato KT, Ryu RK, et al. MR tracking of iron-labeled glass radioembolization microspheres during transcatheter delivery to rabbit VX2 liver tumors: feasibility study. Radiology. 2008;249:845-54. doi:10.1148/radiol. 2491072027.
63. Walrand S, Hesse M, Demonceau G, Pauwels S, Jamar F. Yttrium-90-labeled microsphere tracking during liver selective internal radiotherapy by bremsstrahlung pinhole SPECT: feasibility study and evaluation in an abdominal phantom. EJNMMI Res. 2011;1:32. doi:10.1186/2191-219X-1-32.
64. D'Asseler Y. Advances in SPECT imaging with respect to radionuclide therapy. Q J Nucl Med Mol Imaging. 2009;53:343-7.
65. Minarik D, Sjogreen Gleisner K, Ljungberg M. Evaluation of quantitative (90) Y SPECT based on experimental phantom studies. Phys Med Biol. 2008;53:5689-703. doi:10.1088/0031-9155/53/20/008.
66. Lassmann M. Dosimetry of short-ranged radionuclides. Nuklearmedizin. 2010;49 Suppl 1:S46-9.
67. Rong X, Du Y, Frey EC. A method for energy window optimization for quantitative tasks that includes the effects of model-mismatch on bias: application to Y-90 bremsstrahlung SPECT imaging. Phys Med Biol. 2012;57:3711-25. doi:10.1088/0031-9155/57/12/3711.
68. Ito S, Kurosawa H, Kasahara H, Teraoka S, Ariga E, Deji S, et al. (90) Y bremsstrahlung emission computed tomography using gamma cameras. Ann Nucl Med. 2009;23:257-67. doi:10.1007/s12149-009-0233-9.
69. Knesaurek K, Machac J, Muzinic M, Da Costa M, Zhang Z, Heiba S. Quantitative comparison of yttrium-90 (90Y)-microspheres and technetium-99 m (99mTc)-macroaggregated albumin SPECT images for planning 90Y therapy of liver cancer. Technol Cancer Res Treat. 2010;9:253-62.
70. Sebastian AJ, Szyszko T, Al-Nahhas A, Nijran K, Tait NP. Evaluation of hepatic angiography procedures and bremsstrahlung imaging in selective internal radiation therapy: a two-year single-center experience. Cardiovasc Intervent Radiol. 2008;31:643-9. doi:10.1007/s00270-008-9298-4.
71. Minarik D, Ljungberg M, Segars P, Gleisner KS. Evaluation of quantitative planar 90Y bremsstrahlung whole-body imaging. Phys Med Biol. 2009;54:5873-83. doi:10.1088/0031-9155/54/19/014.
72. Elschot M, Vermolen BJ, Lam MG, De Keizer B, Van Den Bosch MA, De Jong HW. Quantitative comparison of PET and Bremsstrahlung SPECT for imaging the in vivo yttrium-90 microsphere distribution after liver radioembolization. PLoS One. 2013;8:e55742. doi:10. 1371/journal.pone.0055742.
73. Lau WY, Ho S, Leung TW, Chan M, Ho R, Johnson PJ, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys. 1998;40:583-92.
74. Grosser OS, Nultsch M, Laatz K, Ulrich G, Seidensticker R, Pethe A, et al. Radioembolization with (90) Y-labeled microspheres: posttherapeutic therapy validation with Bremsstrahlung-SPECT. Z Med Phys. 2011;21:274-80. doi:10.1016/j.zemedi.2011.05.002.
75. Minarik D, Sjogreen-Gleisner K, Linden O, Wingardh K, Tennvall J, Strand SE, et al. 90Y Bremsstrahlung imaging for absorbed-dose assessment in high-dose radioimmunotherapy. J Nucl Med. 2010;51:1974-8. doi:10.2967/jnumed.110.079897.
76. Rong X, Du Y, Ljungberg M, Rault E, Vandenberghe S, Frey EC. Development and evaluation of an improved quantitative (90) Y bremsstrahlung SPECT method. Med Phys. 2012;39:2346-58. doi: 10.1118/1.3700174.
77. Van Elmbt L, Vandenberghe S, Walrand S, Pauwels S, Jamar F. Comparison of yttrium-90 quantitative imaging by TOF and non-TOF PET in a phantom of liver selective internal radiotherapy. Phys Med Biol. 2011;56:6759-77. doi:10.1088/0031-9155/56/21/001.
78. Lhommel R, Van Elmbt L, Goffette P, Van Den Eynde M, Jamar F, Pauwels S, et al. Feasibility of 90Y TOF PET-based dosimetry in liver metastasis therapy using SIR-Spheres. Eur J Nucl Med Mol Imaging. 2010;37:1654-62. doi:10.1007/s00259-010-1470-9.
79. Willowson K, Forwood N, Jakoby BW, Smith AM, Bailey DL. Quantitative (90) Y image reconstruction in PET. Med Phys. 2012;39:7153-9. doi:10.1118/1.4762403.
80. Kao YH, Tan EH, Ng CE, Goh SW. Yttrium-90 time-of-flight PET/CT is superior to Bremsstrahlung SPECT/CT for postradioembolization imaging of microsphere biodistribution. Clin Nucl Med. 2011;36:e186-7. doi:10.1097/RLU. 0b013e31821c9a11.